TLDR:
Ability Biologics has closed an $18 million seed funding extension led by Amplitude Ventures to develop highly targeted immunomodulators using generative AI. The company’s AbiLeap™ discovery engine utilizes AI to create logic-enabled antibodies for cancer and immune-related disorders. Ability Biologics aims to tackle the challenge of on-target, off-tissue toxicity in antibody therapy.
Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension
Ability Biologics has successfully completed its seed funding round, raising a total of $18 million USD with Amplitude Ventures as the leading investor. Other investors in this round include Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus, and Alexandria Venture Investments.
The company specializes in applying generative AI to therapeutic discovery and is focused on developing potent and selective antibody therapeutics for cancer and immune-related disorders. Through its innovative AbiLeap™ discovery engine, Ability Biologics is generating novel antibodies with logic gating capabilities to target specific tissues and cells within the local microenvironment.
Ability Biologics’ leadership team, with expertise in immunology, antibody discovery, and therapeutic development, is leveraging powerful computational tools to create next-generation antibodies. The company’s platform integrates multiple approaches in a single molecule to enhance specificity and selectivity, aiming to develop potent therapeutics with broad therapeutic windows.
The company’s focus on addressing the challenge of on-target, off-tissue toxicity in antibody therapy sets it apart in the biotech sector. By rapidly developing selective and potent, ultra-targeted biotherapeutics, Ability Biologics aims to enhance potency and patient outcomes.
Investors like Investissement Québec see the potential for artificial intelligence in antibody development as a critical area for the treatment of various diseases, including cancer. With the support of investors and the utilization of cutting-edge technologies, Ability Biologics is dedicated to developing the most potent and selective antibody therapeutics to meet significant unmet medical needs.
